News | February 23, 2024
AstraZeneca completes acquisition of Gracell
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
Furthering cell therapy ambition across oncology and autoimmune diseases
A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
Subscribe To Our Newsletter & Stay Updated
